About MASLD

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease in the United States as well as worldwide, with an estimated prevalence ranging from 25% to 40%. Metabolic associated steatohepatitis (MASH) is the aggressive form of MASLD that can progress to cirrhosis, liver failure, and hepatocellular carcinoma. MASH is also associated with substantial economic burden, inflicting $103 billion of direct medical costs each year in the United States.

---

About the Simulator

MASLD Simulator is an interactive, open-access tool that provides information on the short- and long-term risks associated with MASLD and MASH. It provides patients and providers individualized risk predictions based on person’s risk and demographic factors. The Simulator also aims to increase the awareness of MASH by providing data on mortality and long-term consequences of MASH. The Simulator is based on a clinical-valid mathematical model that simulates the natural history of MASLD. The outcomes of the mathematical model have been validated with three large observational studies. The tool allows users to enter patient demographics and current MASLD stage, and predicts survival, mortality (liver, non-liver, and background), cumulative incidence of liver cancer and decompensated cirrhosis. The Simulator also allows users to compare outcomes between different MASLD stages.